Skip to main content
Top
Published in: Current Rheumatology Reports 6/2010

01-12-2010

Orbital Inflammatory Pseudotumors: Etiology, Differential Diagnosis, and Management

Author: Gabriela M. Espinoza

Published in: Current Rheumatology Reports | Issue 6/2010

Login to get access

Abstract

Orbital inflammation is typically an idiopathic process that occasionally may be identified with a specific local or systemic disease as the causative agent. Orbital inflammatory pseudotumor (also known as idiopathic orbital inflammation syndrome, orbital pseudotumor, nonspecific orbital inflammation, and orbital inflammatory syndrome) is defined as an idiopathic tumor-like inflammation consisting of a pleomorphic cellular response and a fibrovascular tissue reaction. Various rheumatologic disorders are associated with orbital inflammation and must be ruled out in cases of orbital inflammatory pseudotumor, including Wegener’s granulomatosis, giant cell arteritis, systemic lupus erythematosus, dermatomyositis, and rheumatoid arthritis. The mainstay of therapy is corticosteroid therapy, although there is an increasing trend toward use of antimetabolites, alkylating agents, cytotoxic agents, and other immunosuppressive agents.
Literature
1.
go back to reference Jacobs D, Galetta S: Diagnosis and management of orbital pseudotumor. Ophthalmology 2002, 13:347–351. Jacobs D, Galetta S: Diagnosis and management of orbital pseudotumor. Ophthalmology 2002, 13:347–351.
2.
go back to reference Mombaerts I, Goldschmeding R, Schlingemann RO, Koornneef L: What is orbital pseudotumor? Surv Ophthalmol 1996, 41:66–78.CrossRefPubMed Mombaerts I, Goldschmeding R, Schlingemann RO, Koornneef L: What is orbital pseudotumor? Surv Ophthalmol 1996, 41:66–78.CrossRefPubMed
3.
go back to reference Yuen SJA, Rubin PAD: Idiopathic orbital inflammation: ocular mechanisms and clinicopathology. Ophthalmol Clin North Am 2002, 15:121–126.CrossRefPubMed Yuen SJA, Rubin PAD: Idiopathic orbital inflammation: ocular mechanisms and clinicopathology. Ophthalmol Clin North Am 2002, 15:121–126.CrossRefPubMed
4.
go back to reference Alshaikh M, Kakakios AM, Kemp AS: Orbital myositis following streptococcal pharyngitis. J Paediatr Child Health 2008, 44:233–234.CrossRefPubMed Alshaikh M, Kakakios AM, Kemp AS: Orbital myositis following streptococcal pharyngitis. J Paediatr Child Health 2008, 44:233–234.CrossRefPubMed
5.
go back to reference Mackie SL, Keat A: Poststreptococcal reactive arthritis: what is it and how do we know? Rheumatology 2004, 43:949–954.CrossRefPubMed Mackie SL, Keat A: Poststreptococcal reactive arthritis: what is it and how do we know? Rheumatology 2004, 43:949–954.CrossRefPubMed
6.
go back to reference Dale RC, Candler PM, Church AJ, et al.: Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol 2006, 172:187–197.CrossRefPubMed Dale RC, Candler PM, Church AJ, et al.: Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol 2006, 172:187–197.CrossRefPubMed
7.
go back to reference Venuta A, Ferrari P, Beverelli A, et al.: Acute post-streptococcal polymyalgia: two new cases with a review of the literature. Eur J Pediatr 1995, 154:475–476.CrossRefPubMed Venuta A, Ferrari P, Beverelli A, et al.: Acute post-streptococcal polymyalgia: two new cases with a review of the literature. Eur J Pediatr 1995, 154:475–476.CrossRefPubMed
8.
go back to reference Nieto JC, Kim N, Lucarelli MJ: Dacryoadenitis and orbital myositis associated with lyme disease. Arch Ophthalmol 2008, 126:1165–1166.CrossRefPubMed Nieto JC, Kim N, Lucarelli MJ: Dacryoadenitis and orbital myositis associated with lyme disease. Arch Ophthalmol 2008, 126:1165–1166.CrossRefPubMed
9.
go back to reference Kawasaki A, Borruat FX: An unusual presentation of herpes zoster ophthalmicus: orbital myositis preceding vesicular eruption. Am J Ophthalmol 2003, 136:574–575.CrossRefPubMed Kawasaki A, Borruat FX: An unusual presentation of herpes zoster ophthalmicus: orbital myositis preceding vesicular eruption. Am J Ophthalmol 2003, 136:574–575.CrossRefPubMed
10.
go back to reference Badilla J, Dolman P: Orbital myositis involving the oblique muscles associated with herpes zoster ophthalmicus. Ophthal Plast Reconstr Surg 2007, 23:411–413.CrossRefPubMed Badilla J, Dolman P: Orbital myositis involving the oblique muscles associated with herpes zoster ophthalmicus. Ophthal Plast Reconstr Surg 2007, 23:411–413.CrossRefPubMed
11.
go back to reference Volpe NJ, Shore JW: Orbital myositis associated with herpes zoster. Arch Ophthalmol 1991, 109:471–472.PubMed Volpe NJ, Shore JW: Orbital myositis associated with herpes zoster. Arch Ophthalmol 1991, 109:471–472.PubMed
12.
go back to reference Sobrin L, Kim E, Christen W, et al.: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125:895–900.CrossRefPubMed Sobrin L, Kim E, Christen W, et al.: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125:895–900.CrossRefPubMed
13.
go back to reference Garrity JA, Coleman AW, Matteson EL, et al.: Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol 2004, 138:925–930.CrossRefPubMed Garrity JA, Coleman AW, Matteson EL, et al.: Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol 2004, 138:925–930.CrossRefPubMed
14.
go back to reference Atabay C, Tyutyunikov A, Scalise D, et al.: Serum antibodies reactive with eye muscle membrane antigens are detected in patients with nonspecific orbital inflammation. Ophthalmology 1995, 102:145–153.PubMed Atabay C, Tyutyunikov A, Scalise D, et al.: Serum antibodies reactive with eye muscle membrane antigens are detected in patients with nonspecific orbital inflammation. Ophthalmology 1995, 102:145–153.PubMed
15.
go back to reference Yuen SJA, Rubin PAD: Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol 2003, 121:491–499.CrossRefPubMed Yuen SJA, Rubin PAD: Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol 2003, 121:491–499.CrossRefPubMed
16.
go back to reference Lanciano R, Fowble B, Sergott RC, et al.: The results of radiotherapy for orbital pseudotumor. Int J Radiat Oncol Biol Phys 1990, 18:407–411.PubMed Lanciano R, Fowble B, Sergott RC, et al.: The results of radiotherapy for orbital pseudotumor. Int J Radiat Oncol Biol Phys 1990, 18:407–411.PubMed
17.
go back to reference Sergott R, Glaser J, Charyulu K: Radiotherapy for idiopathic inflammatory orbital pseudotumor: indications and results. Arch Ophthalmol 1981, 99:8536. Sergott R, Glaser J, Charyulu K: Radiotherapy for idiopathic inflammatory orbital pseudotumor: indications and results. Arch Ophthalmol 1981, 99:8536.
18.
go back to reference Orcutt J, Garner A, Henk J, Wright J: Treatment of idiopathic inflammatory orbital pseudotumors by radiotherapy. Br J Ophthalmol 1983, 67:570–574.CrossRefPubMed Orcutt J, Garner A, Henk J, Wright J: Treatment of idiopathic inflammatory orbital pseudotumors by radiotherapy. Br J Ophthalmol 1983, 67:570–574.CrossRefPubMed
19.
go back to reference Smitt MC, Donaldson SS: Radiation therapy for benign disease of the orbit. Semin Radiat Oncol 1999, 9:179–189.CrossRefPubMed Smitt MC, Donaldson SS: Radiation therapy for benign disease of the orbit. Semin Radiat Oncol 1999, 9:179–189.CrossRefPubMed
20.
go back to reference Zacharopoulos IP, Papadaki T, Manor RS, Briscoe D: Treatment of idiopathic orbital inflammatory disease with cyclosporine-A: a case presentation. Semin Ophthalmol 2009, 24:260–261.CrossRefPubMed Zacharopoulos IP, Papadaki T, Manor RS, Briscoe D: Treatment of idiopathic orbital inflammatory disease with cyclosporine-A: a case presentation. Semin Ophthalmol 2009, 24:260–261.CrossRefPubMed
21.
go back to reference Bielory L, Frohman LP: Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology 1991, 98:1732–1736.PubMed Bielory L, Frohman LP: Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology 1991, 98:1732–1736.PubMed
22.
go back to reference • Buell C, Koo J: Long-term safety of mycophenolate mofetil and cyclosporine: a review. J Drugs Dermatol 2008, 7:741–748. This was a meta-analysis review of CsA use that examined its safety profile.PubMed • Buell C, Koo J: Long-term safety of mycophenolate mofetil and cyclosporine: a review. J Drugs Dermatol 2008, 7:741–748. This was a meta-analysis review of CsA use that examined its safety profile.PubMed
23.
go back to reference Diaz-Llopis M, Menezo JL: Idiopathic inflammatory orbital pseudotumor and low-dose cyclosporine. Am J Ophthalmol 1989, 107:547–548.PubMed Diaz-Llopis M, Menezo JL: Idiopathic inflammatory orbital pseudotumor and low-dose cyclosporine. Am J Ophthalmol 1989, 107:547–548.PubMed
24.
go back to reference Falcini F, Simonini G, Resti M, Cimaz R: Recurrent orbital pain and diplopia in a 12 year old boy. Ann Rheum Dis 2002, 61:93–94.CrossRefPubMed Falcini F, Simonini G, Resti M, Cimaz R: Recurrent orbital pain and diplopia in a 12 year old boy. Ann Rheum Dis 2002, 61:93–94.CrossRefPubMed
25.
go back to reference Sanchez-Roman J, Varela-Aguilar JM, Bravo-Ferrer J, et al.: Idiopathic orbital myositis: treatment with cyclosporin. Ann Rheum Dis 1993, 52:84–85.CrossRefPubMed Sanchez-Roman J, Varela-Aguilar JM, Bravo-Ferrer J, et al.: Idiopathic orbital myositis: treatment with cyclosporin. Ann Rheum Dis 1993, 52:84–85.CrossRefPubMed
26.
go back to reference • Gumus K, Mirza GE, Cavanagh HD, Karakucuk S: Topical cyclosporine A as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of the literature. Eye Contact Lens 2009, 35:275–278. This case report showed topical corticosteroid and CsA use to control orbital inflammation in a patient who did not achieve control and did not tolerate the side effects of oral corticosteroids and oral CsA.CrossRefPubMed • Gumus K, Mirza GE, Cavanagh HD, Karakucuk S: Topical cyclosporine A as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of the literature. Eye Contact Lens 2009, 35:275–278. This case report showed topical corticosteroid and CsA use to control orbital inflammation in a patient who did not achieve control and did not tolerate the side effects of oral corticosteroids and oral CsA.CrossRefPubMed
27.
go back to reference Smith JR, Rosenbaum JT: A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001, 85:1220–1224.CrossRefPubMed Smith JR, Rosenbaum JT: A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001, 85:1220–1224.CrossRefPubMed
28.
go back to reference Shah SS, Lowder CY, Schmitt MA, et al.: Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992, 99:1419–1423.PubMed Shah SS, Lowder CY, Schmitt MA, et al.: Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992, 99:1419–1423.PubMed
29.
go back to reference Osborne S, Sims JL, Rosser PM: Short-term use of infliximab in a case of recalcitrant idiopathic orbital inflammatory disease. Clin Experiment Ophthalmol 2009, 37:897–900.CrossRefPubMed Osborne S, Sims JL, Rosser PM: Short-term use of infliximab in a case of recalcitrant idiopathic orbital inflammatory disease. Clin Experiment Ophthalmol 2009, 37:897–900.CrossRefPubMed
30.
go back to reference • Sahlin S, Lignell B, Williams M, et al.: Treatment of idiopathic sclerosing inflammation of the orbit (myositis) with infliximab. Acta Ophthalmol 2009, 87:906–908. This case report showed successful treatment with infliximab of a very difficult subset of OIP patients.CrossRefPubMed • Sahlin S, Lignell B, Williams M, et al.: Treatment of idiopathic sclerosing inflammation of the orbit (myositis) with infliximab. Acta Ophthalmol 2009, 87:906–908. This case report showed successful treatment with infliximab of a very difficult subset of OIP patients.CrossRefPubMed
31.
go back to reference Miquel T, Abad S, Badelon I, et al.: Successful treatment of idiopathic orbital inflammation with infliximab: an alternative to conventional steroid-sparing agents. Ophthal Plast Reconstr Surg 2008, 24:415–417.CrossRefPubMed Miquel T, Abad S, Badelon I, et al.: Successful treatment of idiopathic orbital inflammation with infliximab: an alternative to conventional steroid-sparing agents. Ophthal Plast Reconstr Surg 2008, 24:415–417.CrossRefPubMed
32.
go back to reference Prendiville C, O’Doherty M, Moriarty P, Cassidy L: The use of infliximab in ocular inflammation. Br J Ophthalmol 2008, 92:823–825.CrossRefPubMed Prendiville C, O’Doherty M, Moriarty P, Cassidy L: The use of infliximab in ocular inflammation. Br J Ophthalmol 2008, 92:823–825.CrossRefPubMed
33.
go back to reference Wilson MW, Shergy WJ, Haik BG: Infliximab in the treatment of recalcitrant idiopathic orbital inflammation. Ophthal Plast Reconstr Surg 2004, 20:381–383.CrossRefPubMed Wilson MW, Shergy WJ, Haik BG: Infliximab in the treatment of recalcitrant idiopathic orbital inflammation. Ophthal Plast Reconstr Surg 2004, 20:381–383.CrossRefPubMed
Metadata
Title
Orbital Inflammatory Pseudotumors: Etiology, Differential Diagnosis, and Management
Author
Gabriela M. Espinoza
Publication date
01-12-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 6/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0128-8

Other articles of this Issue 6/2010

Current Rheumatology Reports 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine